Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (539)	1/23/2000 12:32:00 PM
From: LLCF	Respond to of 52153

<Some thoughts on the macro question.> And we cannot forget the backdrop to all this in the U.S. which is the demographic factor that bulls have been pounding the table with for years... we've got some explosive years ahead. AND you allude to the 'need to munch' that has also been tossed about quite a bit. It's barely started... I'm sure some big pharma strategists are scratching their heads at this rally... 'oops, guess we should have pulled the trigger.' I may have been pre-mature before, but I think it's now safe to say buyers will pay at least 2x 6 months ago prices... speaking of buyouts, how about the 'internet' model, where E-Bay could by GM and auction cars??? MLNM goes 20 $2000 per share and scoops PNU?? DAK

To: Vector1 who wrote (539)	1/23/2000 5:33:00 PM
From: biowa	Read Replies (1) \| Respond to of 52153

V1, IMO when historians look back to the first 30 years of the 21st century the defining event will not be the internet or telecomunications but the advances in healthcare as a result of understanding the human genome and the therapies that result therefrom. Complete agreement. And my point is directed primarily at the gx cos., since for most of them, they are looking to generate revenues, at least to a significant percent, from royalties that makes their current mkt caps somewhat hard to support at any reasonable multiple of 5 year earnings. In a broader sense this also goes to a point that I think I've brought before - that with an accelerating pace of new drug development are we going to shorten the competitive lifecycle of many new drugs to the point that they will never recoup the cost of development plus a reasonable rate of return? Then again, in this market the idea isn't to buy stocks that make sense; it's to buy stocks that someone else wants worse later <g> biowa